Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive crawled time : 21:00 save search
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
Published: 2024-04-08 (Crawled : 21:00) - globenewswire.com
VINC | $0.955 9.9% 9.01% 410K
|
|
| O: -65.69%
H: 0.84%
C: -35.37%
vip236 pharma association positive cancer pipeline research for meeting
ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
Published: 2024-02-12 (Crawled : 21:00) - globenewswire.com
RMD | $184.22 2.15% 0.0% 1.2M
|
Health Technology
|
| O: -1.57%
H: 1.1%
C: -0.27%
positive therapy
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
Published: 2024-01-18 (Crawled : 21:00) - globenewswire.com
CHRS | $2.19 0.46% 0.46% 810K
|
Health Technology
|
| O: 5.0%
H: 1.59%
C: -3.17%
il-27 symposium asco positive
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference
Published: 2024-01-18 (Crawled : 21:00) - globenewswire.com
AEON | $4.3 -8.9% 0.0% 71K
|
|
| O: 5.73%
H: 4.37%
C: 4.37%
abp-450 conference pre-clinical positive biopharma
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
Published: 2024-01-08 (Crawled : 21:00) - globenewswire.com
AVIR | $3.725 1.5% 1.48% 180K
|
Health Technology
|
| O: 1.61%
H: 11.43%
C: 9.52%
covid-19 hepatitis positive pharmaceuticals virus trial milestone study
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
Published: 2023-12-18 (Crawled : 21:00) - globenewswire.com
CRNX G | $44.21 1.77% 1.74% 610K
|
Health Technology
|
| O: 8.48%
H: 5.02%
C: 2.77%
positive treatment ongoing study
Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Published: 2023-12-15 (Crawled : 21:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.64%
H: 0.21%
C: -1.79%
hyqvia chmp positive therapy
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma
Published: 2023-12-12 (Crawled : 21:00) - globenewswire.com
CCCC | $6.89 0.44% 0.44% 910K
|
Health Technology
|
| O: 35.9%
H: 89.62%
C: 73.27%
cft7455 positive trial therapeutics
IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia
Published: 2023-12-11 (Crawled : 21:00) - globenewswire.com
INAB | $1.035 3.51% 3.39% 280K
|
|
| O: 23.05%
H: 9.84%
C: 3.81%
inb-100 positive update leukemia trial
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023
Published: 2023-12-11 (Crawled : 21:00) - globenewswire.com
STRO | $3.73 -1.06% -1.07% 720K
|
Health Technology
|
| O: 0.28%
H: 1.66%
C: -1.39%
positive biopharma
Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
Published: 2023-12-07 (Crawled : 21:00) - globenewswire.com
ALGS | $0.839 4.74% 4.53% 97K
|
Health Technology
|
| O: 4.62%
H: 5.15%
C: -14.71%
alg-0001 positive therapeutics nash
Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine
Published: 2023-12-06 (Crawled : 21:00) - prnewswire.com
ANIX | $3.06 1.66% 1.63% 73K
|
Health Technology
|
| O: 2.29%
H: 5.63%
C: -10.45%
conference vaccine breast positive cancer ongoing study
Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH
Published: 2023-12-04 (Crawled : 21:00) - globenewswire.com
IVA | $3.3 -0.3% 3.9K
|
Health Technology
|
| O: 0.9%
H: 0.89%
C: -1.56%
positive trial nash
Purple Announces Positive Black Friday/Cyber Monday Weekend Selling Period and Reiterates 2023 Full Year Outlook Ahead of Investor Conferences
Published: 2023-12-04 (Crawled : 21:00) - prnewswire.com
PRPL | $1.61 7.33% 6.83% 390K
|
Miscellaneous
|
| O: 8.99%
H: 2.87%
C: -2.78%
year positive purple
Fresenius Medical Care enters into favorable settlement agreement with U. S. government with positive earnings impact of approx. EUR 175 million - 2023 earnings outlook raised
Published: 2023-11-21 (Crawled : 21:00) - prnewswire.com
FMCQF | $42.034 -0.37% 750
|
Health Services
| Email alert
Add to watchlist
favorable positive care impact medical agreement
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
Published: 2023-11-09 (Crawled : 21:00) - globenewswire.com
VOR | $1.89 3.85% 3.7% 210K
|
|
| O: 7.53%
H: 2.5%
C: -12.0%
conference positive update
Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema
Published: 2023-11-09 (Crawled : 21:00) - ionispharma.com
IONS | $41.85 1.9% 1.86% 630K
|
Health Technology
|
| O: 0.53%
H: 0.38%
C: -2.52%
label positive extension results study
Flotek Reports Third Quarter 2023 Financial Results Driven by Strong Growth in Net Income and First Positive Adjusted EBITDA Quarter Since 2018
Published: 2023-11-07 (Crawled : 21:00) - prnewswire.com
FTK | $3.46 0.58% 0.0% 7.5K
|
Industrial Services
|
| O: 0.74%
H: 0.0%
C: -11.92%
positive financial results growth
Trust Stamp Provides a Business Report and Financial Results for the Quarter and Period Ended September 30, 2023 Including Positive EBITDA for Q3
Published: 2023-11-07 (Crawled : 21:00) - globenewswire.com
IDAI | $0.7697 -1.3% -1.31% 37K
|
|
| O: 5.43%
H: 3.03%
C: -10.91%
report business positive trust financial results
Vibrato Medical Announces Positive Results for Early Feasibility Study of Wearable, Non-Invasive Therapeutic Ultrasound to Treat Chronic Limb-Threatening Ischemia (CLTI)
Published: 2023-11-01 (Crawled : 21:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -1.44%
H: 0.0%
C: -1.88%
positive treat medical results study
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.